NASDAQ:SNTS

Santarus (SNTS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$16,995.00
$16,995.00
52-Week Range
N/A
Volume
54,432 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNTS stock logo

About Santarus Stock (NASDAQ:SNTS)

Santarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company’s marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company’s investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

SNTS Stock News Headlines

Societe Nationale des Telecommunications SONATEL SNTS
Automatic Income (from home)
For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.
Biotech Stock Mailbag: Cardium Therapeutics
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Saints report: CSS earn MIAC men’s hockey sweep of Cobbers
Saints report: CSS men victorious at Augsburg
Santarus Stock Hits New 52-Week High (SNTS)
Cramer's 'Mad Money' Recap: The Knot Worth Tying
5 Stocks Insiders are Buying This Week
See More Headlines
Receive SNTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Santarus and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SNTS
CUSIP
80281730
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

SNTS Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Santarus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Santarus investors own include Baidu (BIDU), Home Depot (HD), Pharmacyclics (PCYC), Yelp (YELP), ACADIA Pharmaceuticals (Acad), Altaba (AABA), Allergan (AGN), Alexion Pharmaceuticals (ALXN) and Cree (CREE).

This page (NASDAQ:SNTS) was last updated on 5/4/2024 by MarketBeat.com Staff

From Our Partners